Latest Communications

18 January 2012
APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.

12 July 2011
MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners

13 June 2011
APR Applied Pharma Research s.a. and Labtec GmbH announce Ondansetron Oral Dispersible Film (“ODF”) is now available for licensing in Europe and selected non European countries, after having received marketing authorization in most countries of Europe.


About Us
Corporate Strategy
Contacts

Consistent with our Mission Statement,
we focus on three areas:

We develop and license added value, innovative healthcare products and technologies on a global basis; (you can visit our

Product Portfolio Section

)

We invest into companies or early stage innovative projects and we provide a balanced mix of capital funding and development know how; (learn more about our investment philosophy and current projects in the Think Tank Section)

We provide added value consultancy R&D Services primarily in Europe and USA using a General Contractor approach (learn more about Services)

Thanks to a unique Business Model and based on a solid set of different specific competencies, we generate an innovation flow through a multidisciplinary approach.




Search results